Skip to content

Closed-loop Oxygen Control for High Flow Nasal Therapy

Safety and Efficacy of a Closed-loop Oxygen Control for High Flow Nasal Therapy in ICU Patients: a Randomized Cross-over Study (The HILOOP Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04965844
Acronym
HILOOP
Enrollment
53
Registered
2021-07-16
Start date
2021-04-27
Completion date
2021-08-10
Last updated
2021-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure, High Flow Nasal Cannula, Hyperoxemia, Hypoxemia, Oxygen Therapy, Respiratory Insufficiency

Keywords

High flow nasal cannula, Nasal high flow, Oxygen close-loop, Hypoxemia, Hyperoxemia

Brief summary

In patients with acute hypoxemic respiratory failure (AHRF), High Flow Nasal Therapy (HFNT) improves oxygenation, tolerance, and decrease work of breathing as compared to standard oxygen therapy by facemask. Current guidelines recommend adjusting oxygen flow rates to keep the oxygen saturation measured by pulse oximetry (SpO2) in the target range and avoid hypoxemia and hyperoxemia. The hypothesis of the study is that closed loop oxygen control increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in ICU patients treated with HFNT.

Interventions

DEVICEOxygen close-loop

The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.

DEVICENo intervention

Manual FiO2 adjustment according to SpO2 values

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (\>17yo) patients admitted to the ICU treated with HFNT for at least 8h * Requiring FiO2 ≥ 30% to keep SpO2 in the target ranges defined by the clinician * Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation.

Exclusion criteria

* Patient with indication for immediate continuous positive airway pressure (CPAP), noninvasive ventilation (NIV), or invasive mechanical ventilation * Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine \> 1 mg/h * Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the Massimo SpO2 sensor, which is displayed by a red or orange colour bar) * Severe acidosis (pH ≤ 7.30) * Pregnant woman * Patients deemed at high risk for need of mechanical ventilation within the next 8 hours * Chronic or acute dyshemoglobinemia: methemoglobin, carbon monoxide (CO) poisoning, sickle cell disease * Tracheotomised patient * Formalized ethical decision to withhold or withdraw life support * Patient under guardianship * Patient deprived of liberties * Patient included in another interventional research study under consent * Patient already enrolled in the present study in a previous episode of acute respiratory failure

Design outcomes

Primary

MeasureTime frameDescription
Percentage of time spent in optimal SpO2 range4 hoursThe optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.

Secondary

MeasureTime frameDescription
Percentage of time spent out of range4 hoursAbove or below the suboptimal limits specified at the begginning of the study
Percentage of time with SpO2 signal available4 hoursTime with SpO2 signal available
Mean SpO2/FiO24 hoursMean oxygenation value
ROX index4 hoursIs a predictor of HFNT success/failure defined as (SpO2/FiO2)/respiratory rate
Percentage of time with SpO2 below 88 and 85 percent4 hoursDuration of time with SpO2 \<85 percent and \<88 percent, respectively
Percentage of time spent in sub-optimal SpO2 range4 hoursSpO2 values outside the optimal range but still within an acceptable limit (2-3 percent above and below the optimal range)
Mean FiO24 hoursMean fraction of inspired oxygen
Percentage of time with FiO2 below 40 percent and above 60%4 hoursPercentage of time that FiO2 is \<40 percent and \>60 percent, respectively
Number of manual adjustments4 hoursFrequency of manual adjustments of FiO2
Number of alarms4 hoursFrequency of alarms
Patient comfort4 hoursComfort score by visual analogic scale (from 0 to 10)
Number of events with SpO2 below 88 and 85 percent4 hoursFrequency of SpO2 decreases \<85 percent and \<88 percent, respectively

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026